tiprankstipranks
Trending News
More News >
Sinovac Biotech (SVA)
NASDAQ:SVA
US Market

Sinovac Biotech (SVA) AI Stock Analysis

Compare
126 Followers

Top Page

SV

Sinovac Biotech

(NASDAQ:SVA)

Rating:50Neutral
Price Target:
Sinovac Biotech's overall score reflects its strong liquidity and balance sheet, offset by poor financial performance and lack of earnings. The technical indicators suggest neutrality, and the valuation appears unattractive due to the negative P/E ratio.

Sinovac Biotech (SVA) vs. SPDR S&P 500 ETF (SPY)

Sinovac Biotech Business Overview & Revenue Model

Company DescriptionSinovac Biotech Ltd. (SVA) is a leading biopharmaceutical company focused on research, development, production, and commercialization of vaccines that protect against infectious diseases. Operating primarily in the healthcare and biotechnology sectors, Sinovac is renowned for its extensive portfolio of vaccines, including those for influenza, hepatitis, and COVID-19. The company is headquartered in Beijing, China, and it plays a crucial role in global public health by providing high-quality vaccines to domestic and international markets.
How the Company Makes MoneySinovac Biotech generates revenue primarily through the sale of vaccines to both government and private sector clients. The company's key revenue streams include domestic sales within China and international sales to countries around the world. Sinovac's COVID-19 vaccine, CoronaVac, has become a significant contributor to its revenue, especially during the global pandemic. Additionally, the company benefits from partnerships and collaborations with various health organizations and governments to support vaccine distribution and immunization programs. Sinovac also invests in research and development to innovate and expand its vaccine offerings, which can lead to new revenue opportunities in emerging markets.

Sinovac Biotech Financial Statement Overview

Summary
Sinovac Biotech's financial performance is mixed. The income statement shows a drastic decline in revenue and a net loss, but the balance sheet is strong with high liquidity and low debt. Cash flow is volatile but has potential for improvement.
Income Statement
45
Neutral
Sinovac Biotech's income statement shows a drastic decline in revenue from 2021 to 2023, with revenue falling from approximately $19.4 billion to $448 million. The company also experienced a significant drop in net income, turning from a profit of $8.5 billion in 2021 to a net loss of $99.9 million in 2023. The gross profit margin declined substantially, indicating challenges in cost management and revenue generation. Despite this, the company exhibited strong profits in earlier years, suggesting potential for recovery.
Balance Sheet
75
Positive
The balance sheet of Sinovac Biotech remains relatively strong, with a significant amount of cash and short-term investments totaling over $11 billion, and a low total debt of $299 million, resulting in a negative net debt position. This indicates high liquidity and financial flexibility. The equity ratio is solid, suggesting a stable capital structure. However, the decline in stockholders' equity from 2021 to 2023 reflects the company's recent financial struggles.
Cash Flow
50
Neutral
The cash flow statement reveals volatility, with operating cash flow turning positive in 2023 after a significant negative cash flow in 2022. Free cash flow remains negative, indicating ongoing challenges in generating cash from operations after capital expenditures. The company has shown strong cash flow generation capability in the past, suggesting potential for improvement if operational issues are addressed.
BreakdownDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue448.27M1.49B19.37B510.62M246.05M
Gross Profit266.75M808.30M18.30B443.44M213.58M
EBITDA-6.03M183.10M17.65B221.76M76.05M
Net Income-99.92M113.87M8.47B110.37M44.93M
Balance Sheet
Total Assets13.66B14.11B16.75B1.90B452.30M
Cash, Cash Equivalents and Short-Term Investments11.22B11.31B13.42B1.18B202.99M
Total Debt298.98M74.67M144.91M136.39M20.27M
Total Liabilities1.64B1.40B2.87B781.20M100.10M
Stockholders Equity8.71B8.92B9.33B746.47M294.02M
Cash Flow
Free Cash Flow-41.69M-1.17B14.63B351.66M28.45M
Operating Cash Flow104.00M-770.75M15.35B479.31M39.07M
Investing Cash Flow-2.93B-5.76B-3.02B-204.76M-42.45M
Financing Cash Flow-76.06M-241.40M-1.90B592.57M1.74M

Sinovac Biotech Risk Analysis

Sinovac Biotech disclosed 71 risk factors in its most recent earnings report. Sinovac Biotech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sinovac Biotech Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
PFPFE
72
Outperform
$137.93B17.588.62%7.09%13.38%
61
Neutral
$1.05B2.4530.06%25.92%
58
Neutral
$25.19B-3.87%0.58%-764.64%
51
Neutral
$7.41B0.36-61.88%2.34%16.99%1.69%
SVSVA
50
Neutral
$460.27M-1.44%850.08%1.98%63.69%
48
Neutral
$10.65B-29.34%-38.25%44.29%
VIVIR
47
Neutral
$717.46M-44.59%-73.79%-5.24%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SVA
Sinovac Biotech
6.47
0.00
0.00%
NVAX
Novavax
6.37
-6.29
-49.68%
PFE
Pfizer
24.19
-2.04
-7.78%
MRNA
Moderna
27.16
-91.59
-77.13%
BNTX
BioNTech SE
106.72
26.36
32.80%
VIR
Vir Biotechnology
5.17
-3.73
-41.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 02, 2025